ARTV Filings — Artiva Biotherapeutics, Inc. - FilingSpy
ARTV
Artiva Biotherapeutics, Inc.
A clinical-stage biotechnology company in San Diego making off-the-shelf natural killer (NK) cell therapies, its lead candidate AlloNK designed to help antibodies destroy B-cells that drive autoimmune diseases like rheumatoid arthritis and lupus. Founded in 2019 as a spin-out of South Korea's GC Cell, it can produce thousands of doses from a single umbilical cord blood donor—a ready-made therapy that doesn't wait for a patient's own cells.
Artiva raised $282.7M in a May 2026 offering, extending its cash runway into 2029 as it prepares a Phase 3 trial for AlloNK.
Artiva secured the funding to reach its next major milestone. The net loss widened to $25.0 million from $21.3 million a year ago as R&D spending rose to support a planned Phase 3 registrational trial for AlloNK, while a May 2026 public offering boosted cash and equivalents to $301.5 million and extended the runway into 2029. The company is now capitalized to generate the pivotal data that will define its future.
Key takeaways
Cash and equivalents rose to $301.5 million at quarter-end, up from $21.0 million in the prior quarter, driven by $282.7 million in net proceeds from a May 2026 public offering.
Management now expects current cash to fund operations into 2029, a two-year extension from the prior 'into the second quarter of 2027' , and plans to initiate a Phase 3 registrational trial for AlloNK in refractory rheumatoid arthritis in the second half of 2026.
The net loss widened to $25.0 million from $21.3 million in the same quarter a year ago, as a $4.6 million increase in research and development expenses was partly offset by a $1.0 million rise in interest income.
What changed
The clinical hold on the AlloNK trial, flagged as a key risk in the prior three filings, is no longer mentioned as an active concern, and the company is now aligned with the FDA on a single registrational trial design, indicating the hold has been resolved.
The cash runway has been extended into 2029 from the 'into Q2 2027' that had been reiterated across the prior four quarters, following the $282.7 million May 2026 public offering.
The timeline for the next data catalyst has shifted: the company now guides to primary data from the Phase 3 registrational trial in the second half of 2028, replacing the earlier focus on initial Phase 2a data that was reported in the first quarter of 2026.
What to watch
The initiation of the Phase 3 registrational trial for AlloNK in refractory rheumatoid arthritis, expected in the second half of 2026, and any details on trial design and enrollment timelines.
The quarterly rate against the new 2029 runway, to assess whether the burn rate accelerates as the registrational trial begins.
Any announcement of a partnership or collaboration that could provide non- funding or validation for the NK cell therapy platform ahead of the Phase 3 data readout.
Section summaries
Management's Discussion and Analysis
Net loss widened to $48.5M in H1 2026 driven by a $6.3M increase in R&D for AlloNK autoimmune trials; cash of $349.4M is expected to fund operations into 2029.
⌄
R&D expenses rose $6.3M to $41.2M in H1 2026, primarily from higher external costs for AlloNK clinical trials in autoimmune diseases and increased personnel.
General and administrative expenses were flat at $10.1M in H1 2026, with higher personnel costs offset by lower operational and legal costs.
Research and development expenses rose to $21.9 million from $17.8 million a year ago, primarily from higher external costs for the ongoing AlloNK autoimmune clinical trials and increased personnel costs.
was $20.4 million for the quarter, compared to $23.0 million a year ago and $21.0 million in the prior quarter, reflecting the continued investment in AlloNK clinical development.
The company's reached $379.1 million, and it has no approved products or , with its last collaboration recognized in 2024.
Primary data from the Phase 3 registrational trial, expected in the second half of 2028, which will be the definitive efficacy readout for AlloNK.
Net loss increased to $48.5M in H1 2026 from $41.6M in H1 2025, driven by higher operating expenses and a $0.6M decrease in interest income.
Cash, equivalents, and investments totaled $349.4M as of June 30, 2026, bolstered by $282.7M in net proceeds from a May 2026 public offering.
Management expects current cash will fund operations into 2029, with a Phase 3 registrational trial for AlloNK in refractory RA initiating in H2 2026 and primary data expected in H2 2028.
The company has no product and will require substantial additional funding to support ongoing development and potential future commercialization.
Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined in Item 10(f)(1) of Regulation S-K and are not required to provide the information otherwise required under this item.
⌄
We are a smaller reporting company as defined in Item 10(f)(1) of Regulation S-K and are not required to provide the information otherwise required under this item.
From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, li…
⌄
From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
We are a clinical-stage biopharma with no approved products, significant losses, and substantial capital needs to advance our lead NK cell therapy candidate, AlloNK.
⌄
We have a limited operating history, have never generated product , and expect to incur significant losses for the foreseeable future, with a $379.1M as of June 30, 2026.
Our business is substantially dependent on the success of our lead product candidate, AlloNK, which is in clinical development for autoimmune diseases, a novel and unproven therapeutic area for cell therapy.
We will need substantial additional funding to complete development and commercialization; our current cash of $349.4M is estimated to fund operations into 2029, but this is based on assumptions that may prove wrong.
Newly emphasized risks include the potential adverse impact of international trade policies, including tariffs on pharmaceutical ingredients, and challenges in managing organizational growth as we expand from 115 employees.
Our novel NK cell therapy platform faces significant regulatory uncertainty, as no NK cell therapy is approved, and the FDA or other regulators may impose new requirements, delay trials, or not approve our product candidates.
We rely heavily on third parties for clinical trials, manufacturing, and key intellectual property licensed from GC Cell, and any disruption or termination of these relationships could materially harm our development and commercialization efforts.